DNAPrint Genomics

DNAPrint Genomics OCF Margin

The Operating Cash Flow Margin of DNAPrint Genomics (DNAG) as of Sep 25, 2026 is -237.64 %.

OCF Margin

-237.64 %

Last updated:

Operating Cash Flow Margin of DNAPrint Genomics is 2026 -237.64 % . Operating Cash Flow Margin of DNAPrint Genomics was 2025 - . It decreases by % lower compared to the previous year.

The DNAPrint Genomics OCF Margin history

The DNAPrint Genomics OCF Margin history
YEAROCF MarginYoY
-237.64 %—
Access this data via the Eulerpool API

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DNAPrint Genomics stock

Operating Cash Flow Margin of DNAPrint Genomics is -237.64 % in 2026.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's DNAPrint Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics